Hansa Biopharma AB (publ)
HNSBF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.01 | 0.16 | -0.01 |
| FCF Yield | -3.73% | -5.57% | -7.47% | -9.19% |
| EV / EBITDA | -22.38 | -15.52 | -387.41 | -17.22 |
| Quality | ||||
| ROIC | -31.64% | -27.53% | -20.78% | -26.24% |
| Gross Margin | 34.72% | 62.82% | 69.06% | 58.29% |
| Cash Conversion Ratio | 0.60 | 0.62 | 4.10 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.70% | 7.38% | 6.97% | 3.50% |
| Free Cash Flow Growth | 91.50% | 26.75% | 26.27% | -39.00% |
| Safety | ||||
| Net Debt / EBITDA | -4.89 | -3.35 | -105.89 | -3.97 |
| Interest Coverage | -14.46 | -11.62 | -3.17 | -1.38 |
| Efficiency | ||||
| Inventory Turnover | 5.70 | 6.20 | 7.10 | 5.17 |
| Cash Conversion Cycle | 340.39 | 420.43 | 314.33 | 173.65 |